Lamivudine increases hyperbilirubinemic risk in patients with severe hepatitis

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: KIM, Sang Geon (Seoul National University, Seoul, Korea, Republic Of)
  • Co-author(s): Sang Geon Kim:
    Young Hee Choi: College of Pharmacy, Dongguk University, Korea, Republic Of
  • Abstract:

    Background

    Lamivudine is effective against hepatitis B virus infection recovering alanine aminotransferase (ALT) to normal ranges through virus eradication. Also, total bilirubin (TB) represents an improvement of liver function from virus infection. Despite its effectiveness, a few case reports raised the possibility that lamivudine causes liver..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login